Terumo Corporation

Terumo Corporation

Financial Results for the Third Quarter of Fiscal Year
Ending March 31, 2020 (FY2019)

February 6, 2020

Naoki Muto, Executive Officer
Chief Accounting and Financial Officer (CAFO)

PLAY LIST

from the beginning

Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2020 (FY2019)
  • Highest-ever Q3YTD Revenue and Adjusted Operating Profit
  • Adjusted Operating Profit Variance Analysis
  • FX Impact on Adjusted Operating Profit Variance Analysis
  • Revenue by Region
  • Revenue by Business Segment
  • Cardiac and Vascular: Positive Growth in All Businesses. Continued Double Digit Growth in Profit
  • General Hospital: Revenue and Profit in Line with the Guidance
  • Blood Management: Solid Momentum Excluding FX Impact
  • Reiterate the FY19 Guidance
  • Major Topics in FY19 Q3
  • New Products Pipeline in FY19
Reference
  • FY19 Q3YTD Revenue and Growth by Region
  • Operating Expenses
  • Quarterly Results
  • Adjusted Operating Profit : Adjustments
  • CAPEX and R&D Expenses
  • Cash Flows
  • Foreign Exchange Sensitivity
  • The Status of Convertible Bonds
IR Contact
  • Back
  • Next

Download

  • Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2020 (FY2019)(PDF 856 KB)
  • "IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020 "(PDF 1.2 MB)
  • Questionnaire Please answer the questionnair
  • Forward-Looking Statements
    System Requirements
GreenPower
link corporate communications